An official website of the United States government
Here's how you know
Official websites use .mil
A
.mil
website belongs to an official U.S. Department of Defense organization in the United States.
Secure .mil websites use HTTPS
A
lock (
lock
)
or
https://
means you’ve safely connected to the .mil website. Share sensitive information only on official, secure websites.
Skip to main content (Press Enter).
Toggle navigation
JPEO-CBRND
Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense
JPEO-CBRND
Search Joint Program Executive Office for Chemical, Biological Defense (JPEO-CBRND):
Search
Search
Search Joint Program Executive Office for Chemical, Biological Defense (JPEO-CBRND):
Search
Home
About
Leadership
Joint Project Managers & Joint Project Leads
Our Story
Resources
Media
News
Photography
Work With Us
JETT - Joint Enterprise Technology Tool
SPARK
Careers
Contact
News
1
2
3
4
5
Results:
Tag:
COVID -19
Biden Administration announces U.S. government procurement of Merck’s investigational antiviral medicine for COVID-19 treatment
June 9, 2021
— The Biden Administration today announced that the U.S. government will procure approximately 1.7 million courses of an investigational antiviral treatment, molnupiravir (MK-4482), for COVID-19 from Merck, pending emergency use authorization (EUA) or approval from the U.S. Food and Drug Administration (FDA).Molnupiravir (MK-4482) is designed to...
MORE
Memorandum of Understanding for Acquisition Support Signed Between the Department of Defense and the Department of Health and Human Services
May 26, 2021
— On May 20, 2021, Deputy Secretary of Defense Kathleen Hicks and Deputy Secretary of Health and Human Services (HHS) Andrea Palm signed a memorandum of understanding (MOU) to continue the agencies’ partnership in defeating COVID-19 and preparing for future public health emergencies.The MOU establishes the framework under which the Department of...
MORE
Interview with Dr. Kevin Wingerd Chief Technology Officer at the Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical)
May 25, 2021
— Excerpt from NCT Magazine's Interview with Dr. Kevin Wingerd, Chief Technology Officer at the Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical)...
MORE
The COVID-19 Pandemic: Acquisition of Diagnostic Equipment and Testing Assays for COVID-19 Lays the Groundwork for Vaccine and Treatment Success
May 25, 2021
— In early 2020, the world as we knew it began to change. Lockdowns, mask mandates, and travel bans became the new normal as the world fought to slow the spread of the coronavirus (COVID-19).Priorities began to shift, and the development of safe and efficacious vaccines and therapeutics for COVID-19, along with the diagnostic capability needed to...
MORE
DOD & HHS Announce DPA Title III Agreement With Retractable Technologies, Inc. to Expand Domestic Production Capacity for Low Dead-Space Safety Syringes and Needles
May 24, 2021
— As part of the national response to COVID-19, the Department of Defense (DOD), in coordination with the Department of Health and Human Services (HHS), signed an agreement with Retractable Technologies, Inc. (RTI) to expand the production of the low dead-space (LDS) safety syringes and needles. Government funding allocated was $27.3 million.LDS...
MORE
Sanofi-GSK report positive interim results for their COVID-19 shot
May 17, 2021
— An experimental COVID-19 vaccine developed by Sanofi and GlaxoSmithKline showed a robust immune response in early-stage clinical trial results, enabling them to move to a late-stage study, the French drugmaker said on Monday...
MORE
Using Ultrasound Stimulation to Reduce Inflammation in COVID-19 In-Patients
May 12, 2021
— Researchers at University of California San Diego School of Medicine have begun a pilot clinical trial to test the efficacy of using ultrasound to stimulate the spleen and reduce COVID-19-related inflammation, decreasing the length of hospital stays...
MORE
INOVIO Announces Positive Data from Phase 2 Segment of Clinical Trial Evaluating INO-4800, its COVID-19 DNA Vaccine
May 10, 2021
— INO-4800 was shown to be safe, well-tolerated and immunogenic in all age groups. Phase 2 results informed INOVIO's selection of 2.0 mg dose for the Phase 3 segment of the trial...
MORE
Immunome SARS-CoV-2 Antibody Cocktail Neutralizes UK, South Africa, Brazil and California Variants in Preclinical Testing; Progressing Towards IND Filing
April 26, 2021
— In July 2020, Immunome was awarded a $13.3 million agreement from the U.S. Department of Defense's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), in collaboration with the Defense Health Agency, to support Immunome’s COVID program. The research discussed in this press release is part of that program...
MORE
SAB Biotherapeutics Doses First Patient with SAB-185 for the Treatment of COVID-19 in NIH’s ACTIV-2 Phase 2/3 Clinical Trial
April 21, 2021
— https://finance.yahoo.com/news/sab-biotherapeutics-doses-first-patient-200200245.html
MORE
1
2
3
4
5
News Search
News Archive - Search by Year and Month
2024 (34)
2023 (36)
2022 (31)
2021 (37)
2020 (15)
2019 (11)
2018 (5)
2017 (9)
2016 (1)
JPEO-CBRND Press Kit
Download our press kit, which includes helpful documents to better understand our work, such as – Command Brief, Chemical Biological Defense Program's Enterprise strategy, the JPEO-CBRND's Capabilities Catalog, Leadership Biographies, COVID-19 fact sheets, and contracting overview documents.
JPEO-CBRND Public Affairs Office
The JPEO-CBRND Public Affairs Office coordinates and responds to all public affairs and media relations needs on behalf of the JPEO-CBRND. To request a speaker, subject matter expert, or for other interview or request for comment please email our Public Affairs Office email below.